1. Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease 
Saiko Kurosawa, Kumi Oshima, Takuhiro Yamaguchi, Atsumi Yanagisawa, Takahiro Fukuda, Heiwa Kanamori, Takehiko Mori, Satoshi Takahashi, Tadakazu Kondo, Akio Kohno, Koichi Miyamura, Yukari Umemoto, Takanori Teshima, Shuichi Taniguchi, Takuya Yamashita, Yoshihiro Inamoto, Yoshinobu Kanda, Shinichiro Okamoto, Yoshiko Atsuta 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 10, Pages (October 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1 Enrollment of patients.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Overview of SF-36 summary scores and VAS. The boxplots of the SF-36 summary scores and VAS by patients and physicians for all 1140 patients are shown. The boxes represent quartiles and the whiskers the 5th and 95th percentiles.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
The SF-36 PCS, MCS, RCS, and FACT-BMT total scores adjusted for background covariates are presented. Scores of patients with no, mild, moderate, or severe GVHD according to NIH criteria or different IS therapy status were compared. The mean SF-36 summary score of 50 for the general population is indicated by vertical dotted lines. (A) QoL by NIH global severity score. (B) QoL by NIH organ-specific severity score. Patients with severe symptoms were not included in the analysis for the mouth, GI tract, liver, joints and fascia, and genital tract. (C) QoL by IS therapy status at the time of survey: no IS therapy, CNIs only, or steroids.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 3
The SF-36 PCS, MCS, RCS, and FACT-BMT total scores adjusted for background covariates are presented. Scores of patients with no, mild, moderate, or severe GVHD according to NIH criteria or different IS therapy status were compared. The mean SF-36 summary score of 50 for the general population is indicated by vertical dotted lines. (A) QoL by NIH global severity score. (B) QoL by NIH organ-specific severity score. Patients with severe symptoms were not included in the analysis for the mouth, GI tract, liver, joints and fascia, and genital tract. (C) QoL by IS therapy status at the time of survey: no IS therapy, CNIs only, or steroids.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

6. Figure 4
VAS scores from patients and physicians for patients with no, mild, moderate, or severe GVHD by NIH global severity score are shown. Scores were adjusted for background covariates.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions